News
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other injectable GLP-1 weight loss drugs, such as Lilly’s Mounjaro and Novo Nordisk’s Ozempic.
The results Lilly is reporting for its oral pill come as another big drug company, Pfizer, has decided to discontinue its ...
Zacks Investment Research on MSN3d
Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?Eli Lilly and Company’s LLY shares have lost 8.2% in the past month. A lot of this price decline is due to the global ...
The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback